When capturing a scleral image in the biometry occasionally an error message can appear as “not enough vessels near the limbus have been found”, in consequence, using the intraoperative toric axis assistant is not possible. Timolol 0.25% is a common and available non-selective beta-adrenergic blocker. The use of topical timolol 0.25% drops as an effective method to enhance preoperative limbal vessels reference image is discussed in this touchOPHTHALMOLOGY interview with Dr Eduardo Roditi (Westmead Hospital, Sydney, Australia) as well as the clinical implications of these findings, and what further study is needed.
The presentation entitled ‘Topical Timolol 0.25% to Enhance Preoperative Reference Vessels Image in Digitally Assisted Intraoperative Axis Alignment for Toric IOL’ was presented at the American Society of Cataract and Refractive Surgery, April 22-26, 2022
Dr Eduardo Roditi won the first prize in the ASCRS 2022 film awards in home production.
- What are the challenges of identification of limbal vessels in intraoperative digital axis alignment?
- What is the rationale for using timolol 0.25% drops to enhance preoperative limbal vessels?
- Could you tell us about the case study you are reporting?
- What are the clinical implications of these findings, and what further study is needed?
Disclosures: Eduardo Roditi has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ASCRS 2022.
Share this Video
Related Videos In Anterior Segment
John D Sheppard, Hawaiian Eye and Retina 2023: Phaco and keratopathy – sequential or combined keratoplasty?
It was a pleasure to have the opportunity to meet with Dr John D Sheppard (Eastern Virginia Medical School, Norfolk, VA, USA) about his presentation on what to consider when choosing between sequential or combined keratoplasty. Questions: What are the advantages and disadvantages of combined phacoemulsification and keratoplasty versus sequential surgery? (0:10) What patient factors […]
John D Sheppard, Hawaiian Eye and Retina 2023: Highlights
We were delighted to speak with Dr John D Sheppard (Eastern Virginia Medical School, Norfolk, VA, USA) about his highlights from Hawaiian Eye and Retina 2023, and his views on the role of penetrating keratoplasty in the era of selective lamellar keratoplasty. Questions: What have you gained most from attending the Hawaiian Eye meeting? (0:09) […]
Chhavi Saini, ASCRS 2022: Clinical outcomes of Boston keratoprosthesis type 2
The Boston Keratoprosthesis type II (BK2) device may be the only viable option to salvage vision in patients with severe cicatrizing ocular surface disease. The prior BK2 model was modified to the present day (click-on) model in 2009. The clinical outcomes of the current click-on BK2 model is discussed in this touchOPHTHALMOLOGY interview with Dr […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!